Five things to know:
1. Dr. Bohen will remain in his position as CMO until the drugmaker names a successor.
2. The company didn’t disclose why Dr. Bohen, who has been with the company for less than four years, is leaving.
3. Dr. Bohen’s departure comes just a few weeks after Bahija Jallal, AstraZeneca’s former head of its Medimmune unit and Mark Mallon, former product and portfolio chief, left the company.
4. The news comes just a few days after AstraZeneca announced plans to restructure. Last week, AstraZeneca said it will reorganize its research and development into two distinct units — cardiovascular and respiratory drugs and cancer drugs.
5. José Baselga, MD, PhD, former physician-in-chief and CMO at Memorial Sloan Kettering Cancer Center in New York City, was selected to run its newly formed cancer-focused unit. He resigned from Memorial Sloan after reports surfaced that he failed to disclose his drug industry ties in more than 100 research papers. Veteran research head Mene Pangalos was selected to oversee the cardiovascular and respiratory drug unit.
Read the full report here.
More articles on pharmacy:
Hospital-owned drug company attracts 12 more health systems
How nurses are becoming integral to pharma marketing: 7 notes
4 tips for managing drug spend from Alameda Health System’s Dr. Yi-Chih Peng
